DR ‹ › Oncorad Group, a leading oncology player in Morocco and Africa, has signed a partnership agreement with UM6P CoreLabs, the genetics laboratory of Mohammed VI Polytechnic University, to sustainably strengthen access to advanced genetic testing across Morocco. The initiative aims to fully integrate medical genetics into patient care pathways and respond to the growing needs of physicians and patients, Oncorad said in a press release on Monday. For more than four years, the group has relied on genetic testing to tailor treatment protocols and implement personalized targeted therapies in line with international recommendations, benefiting both its own patients and those referred by public and private healthcare providers nationwide. However, the rising volume of genetic test prescriptions has highlighted a major challenge: reliance on foreign platforms, resulting in longer turnaround times, higher costs, and disruptions in medical follow-up. To address this, Oncorad is now structuring a local medical genetics offering that enables analyses to be carried out in Morocco, supported by the high-level scientific and technological infrastructure of UM6P CoreLabs. This local capacity allows Oncorad to maintain high analytical quality standards while better controlling costs and turnaround times. For prescribers, it offers easier access to locally performed genetic tests with faster results and improved interpretation workflows. For patients, it means quicker care, more affordable costs adapted to the national socio-economic context, and greater continuity in therapeutic follow-up. Beyond patient care, the initiative also aims to support the development of a national precision medicine ecosystem by encouraging data sharing, research, and training to advance medical innovation in Morocco.
